(Dr's Monk/Vergote) CME - video - Imedex ELC : Best of the Day: 17th International Meeting of the European Society of Gynaecological Oncology (ESGO)

Discusses also OCEAN/GOG Avastin trials/PARP inhibitors ... Release Date: Sept 13/2011
Expiration Date:  Sept 13/2012

National Comprehensive Cancer Network - New Paradigms in Advanced Ovarian Cancer CME - Dr Deborah K. Armstrong (repeat post)

Note: requires registration to view (free)

New Paradigms in Advanced Ovarian Cancer
Presented by:                       Deborah K. Armstrong,  MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins   Supported by educational grants from Centocor Ortho Biotech and Genentech BioOncology.

June MDcme - Ovarian Cancer online course July 2011

Ovarian Cancer, an online course - JULY 2011

This course will present content in three units - determining risk, diagnosis and concludes with techniques for offering hope and support to your patients.

CME -- the Oncologist: Bevacizumab (Avastin): Concise Drug Review

Take this course

(Note: may require a subscription)

Clinical Care Options - CME - Dr Maurie Markman updated CME March 3, 2010

Note: requires Password/Registration (free):

Oncology - Ovarian Cancer
Authors: Maurie Markman, MD
Date Released: October 01, 2009
Last Updated: March 03, 2010

Table of Contents

• Ovarian Cancer
  • Introduction
  • BRCA Mutations in Ovarian Cancer
  • Screening for Ovarian Cancer
  • Symptoms of Ovarian Cancer
  • Surgical Staging of Ovarian Cancer
  • Primary Surgical Cytoreduction in Ovarian Cancer
  • Interval Surgical Cytoreduction and Neoadjuvant Chemotherapy
  • Chemotherapy for High-Risk Early-Stage Ovarian Cancer
  • Primary Chemotherapy of Advanced Stage Ovarian Cancer
    • Intraperitoneal Chemotherapy of Small-Volume Residual Ovarian Cancer
    • Maintenance Therapy of Advanced Ovarian Cancer
  • Second-Line Therapy of Ovarian Cancer
  • Platinum-Sensitive vs Platinum-Resistant Recurrent Ovarian Cancer
  • Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
  • Treatment of Platinum-Resistant Ovarian Cancer
  • Intermediate Platinum Sensitivity
  • Carboplatin Hypersensitivity Reactions
  • Other Management Options in Recurrent/Resistant Ovarian Cancer
  • Future Research Directions in Ovarian Cancer
  • Tables and Figures
  • References